A year later, the synergic effect of metformin and rapamycin was evaluated in a pancreatic cancer cell line (SW1990) where a reduced cell proliferation was observed, moreover, cell viability was also reduced when cells were treated with both rapamycin and metformin, importantly, an evaluation of phosphorylated mTOR showed that only a combination of the two drugs was capable to suppress the mTOR pathway. This evidence concerns the gene MTOR and familial pancreatic carcinoma.